Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

摘要: Background: Long-term effects of lamivudine treatment on chronic hepatitis B patients without advanced disease remain unknown. Our aim was to investigate the long-term and lamivudineresistant virus (YMDD) development cirrhosis hepatocellular carcinoma (HCC) in asymptomatic disease. Methods: One hundred forty-two e antigen (HBeAg)-positive (median age: 33.9 years) duration: 89.9 months) 124 HBeAg-positive controls 33.4 were prospectively followed up. Patients monitored for HCC, liver biochemistry, (HBV) DNA levels, HBeAg seroconversion flares. YMDD mutations (YMDD-MT) determined annually. Results: Lamivudine-treated had a significantly lower cumulative rate and/or HCC compared with (P=0.005). YMDD-MT occurred 76.3% after 8 years treatment. When YMDD-MT, greatest reduction HBV bilirubin slowest decline albumin level, highest lowest risk flare. still developing (P=0.024) greater (P=0.001) comparison controls. similar chance flares hepatic decompensation. Conclusions: associated reduced Although benefits from therapy, outcome these better than untreated patients.